Vinorelbine
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | NAVELBINE | — | 2001-10-02 – 2002-11-05 | fda.gov ↗ |
| Approved | US (FDA) | NAVELBINE | — | 1994-12-23 | fda.gov ↗ |
Trials 331 · started per year
Also used as a comparator or background therapy in 190 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 116 trials | ||||||
| Phase 1 | NCT05299164 Background | May 2022 → Dec 2023 overdue | non-Hodgkin lymphoma | Institute of Hematology & Blood Diseases Hospital, China | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04648033 Background | Dec 2020 → Oct 2023 | non-small cell lung carcinoma | University of Oxford | Completed | No outcome recorded |
| Phase 1 | NCT04398108 Background | Aug 2020 → Apr 2021 | HER2 positive breast carcinoma | Zai Lab (Shanghai) Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04299113 Background | May 2020 → Dec 2026 expected | rhabdomyosarcoma | Jonsson Comprehensive Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT01684111 Background | Jun 2013 → Jan 2016 | non-small cell lung carcinoma | Aktion Bronchialkarzinom e.V. | Completed | No outcome recorded |
| Phase 1 | NCT01683682 Background | Apr 2013 → Jan 2015 | non-small cell lung carcinoma | Aktion Bronchialkarzinom e.V. | Completed | No outcome recorded |
| Phase 1 | NCT01802970 Background | Dec 2012 → Jan 2017 | breast cancer | Baylor Research Institute | Completed | No outcome recorded |
| Phase 1 | NCT01884428 Background | Jul 2011 → Mar 2014 | Hodgkins lymphoma | Armando Santoro, MD | Unknown | No outcome recorded |
| Phase 1 | NCT01104259 Background | Jul 2010 → Feb 2015 | BRCA1-related cancer predisposition, BRCA2-related cancer predisposition, male breast carcinoma, triple-negative breast carcinoma | University of Washington | Completed | No outcome recorded |
| Phase 1 | NCT01118676 Background | Mar 2010 → Apr 2015 | non-small cell lung carcinoma | Institut Claudius Regaud | Completed | No outcome recorded |
| Phase 1 | NCT00801151 Background | Jan → Oct 2009 | cancer | Institut Claudius Regaud | Terminated | No outcome recorded |
| Phase 1 | NCT00773188 Background | Dec 2008 → Oct 2010 | non-small cell lung carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT00455572 Background | May 2007 → Aug 2013 | non-small cell lung carcinoma | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 1 | NCT00462787 Background | Apr 2007 → Nov 2013 | leukemia | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00477035 Background | May 2006 → Mar 2011 | leukemia, plasma cell myeloma | Sally Arai | Completed | No outcome recorded |
| Phase 1 | NCT00002887 Background | Jul 1995 → ? | lung cancer | Ottawa Regional Cancer Centre | Unknown | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT07131345 Background | Sep 2025 → Oct 2026 expected | malignant mesothelioma | National Cancer Center, China | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06775236 Comparator | Mar 2025 → Jun 2027 expected | breast cancer | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05300282 Background | Feb 2023 → Apr 2027 expected | Hodgkins lymphoma | Fondazione Italiana Linfomi - ETS | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04145349 Background | Jan 2020 → Jun 2024 | desmoplastic small round cell tumor | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1/2 | NCT01254136 Background | Oct 2010 → Sep 2011 | breast cancer | Incyte Corporation | Terminated | No outcome recorded |
| Phase 279 trials | ||||||
| Phase 2 | NCT07420439 Comparator | May 2026 → Aug 2028 expected | interstitial lung disease, non-small cell lung carcinoma | French Cooperative Thoracic Intergroup | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07203729 Comparator | Mar 2026 → Jun 2030 expected | breast cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT06875128 Background | Jan 2026 → May 2029 expected | — | Delcath Systems Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT07007559 Background | Dec 2025 → Dec 2027 expected | breast cancer | ALX Oncology Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT07001618 Comparator | Nov 2025 → Sep 2030 expected | non-small cell lung carcinoma | Gustave Roussy, Cancer Campus, Grand Paris | Recruiting | No outcome recorded |
| Phase 2 | NCT07137884 Comparator | Oct 2025 → Oct 2028 expected | rhabdomyosarcoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06875076 Background | Mar 2025 → Jan 2028 expected | malignant pleural mesothelioma | The First Hospital of Jilin University | Recruiting | No outcome recorded |
| Phase 2 | NCT06678048 Background | Oct 2024 → Apr 2026 overdue | breast cancer | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT06102824 Comparator | Oct 2024 → Jun 2027 expected | Her2-receptor negative breast cancer | Guangdong Provincial People's Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06771609 Comparator | Sep 2024 → Sep 2028 expected | triple-negative breast carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT06489808 Background | May 2024 → Dec 2026 expected | aggressive B-cell non-Hodgkin lymphoma | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| Phase 2 | NCT06355037 Background | May → Dec 2024 overdue | triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT06424899 Background | May 2024 → May 2027 expected | non-small cell lung carcinoma | Zeng Jian | Recruiting | No outcome recorded |
| Phase 2 | NCT06355024 Background | May 2024 → Jan 2025 | triple-negative breast carcinoma | Fudan University | Completed | No outcome recorded |
| Phase 2 | NCT06229067 Background | Jan 2024 → Jan 2025 overdue | triple-negative breast carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06244368 Background | Jan 2024 → Dec 2025 overdue | diffuse large B-cell lymphoma, peripheral T-cell lymphoma, not otherwise specified | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| Phase 2 | NCT05842525 Background | Oct 2023 → May 2024 | colorectal cancer | Hunan Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05594095 Background | Dec 2022 → Dec 2025 overdue | female breast carcinoma, hormone receptor-positive breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT05621434 Background | Dec 2022 → Dec 2024 | HER2 positive breast carcinoma | Fujian Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT05420779 Comparator | Jun 2022 → Dec 2024 | breast carcinoma | Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT05296577 Comparator | Mar 2022 → Sep 2024 | breast cancer | Henan Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04765709 Background | Sep 2021 → Jan 2025 | non-small cell lung carcinoma | Mario Negri Institute for Pharmacological Research | Terminated | No outcome recorded |
| Phase 2 | NCT04681287 Background | Apr → Nov 2021 | HER2 positive breast carcinoma | Henan Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04745975 Comparator | Feb 2021 → Jan 2023 | triple-negative breast carcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT03770299 Background | Jan 2021 → Mar 2023 | non-small cell lung carcinoma | Bristol-Myers Squibb | Withdrawn | No outcome recorded |
| Phase 2 | NCT04681911 Background | Sep 2020 → Sep 2023 | breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 2 | NCT04262804 Background | Jan 2020 → Sep 2021 | breast carcinoma | Zai Lab (Shanghai) Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT03656094 Background | Nov 2018 → Nov 2020 | non-small cell lung carcinoma | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT03442673 Comparator | Sep 2018 → Mar 2023 | plasma cell myeloma | Insel Gruppe AG, University Hospital Bern | Completed | No outcome recorded |
| Phase 2 | NCT03618550 Background | Aug 2018 → Aug 2027 expected | Hodgkins lymphoma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT03242616 Comparator | Feb 2017 → Dec 2023 | breast neoplasm | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02977169 Background | Nov 2016 → Dec 2021 | non-small cell lung carcinoma | Shanghai Chest Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT02940990 Background | Nov 2016 → Dec 2019 | non-small cell lung carcinoma | Shanghai Chest Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT02733380 Background | May 2016 → May 2020 | diffuse large B-cell lymphoma | Henan Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT02139904 Comparator | Mar 2016 → Mar 2021 | malignant pleural mesothelioma | Wales Cancer Trials Unit | Completed | No outcome recorded |
| Phase 2 | NCT02610140 Comparator | Dec 2015 → May 2017 | mesothelioma | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT03620032 Background | Nov 2015 → Nov 2022 | diffuse intrinsic pontine glioma | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Unknown | No outcome recorded |
| Phase 2 | NCT02585388 Background | Oct 2015 → May 2017 | breast cancer | ARCAGY/ GINECO GROUP | Terminated | No outcome recorded |
| Phase 2 | NCT02489409 Background | Oct 2015 → May 2018 | breast cancer | Xinjiang Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT02448420 Comparator | Jul 2015 → Sep 2023 | breast cancer | SOLTI Breast Cancer Research Group | Completed | No outcome recorded |
| Phase 2 | NCT02489903 Comparator | Jun 2015 → Dec 2021 | malignant epithelial tumor of ovary, non-small cell lung carcinoma, small cell carcinoma | EpicentRx, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02229149 Background | Dec 2014 → Jan 2022 | breast cancer | US Oncology Research | Terminated | No outcome recorded |
| Phase 2 | NCT02223611 Comparator | Dec 2014 → Dec 2016 | non-small cell lung carcinoma | Hebei Medical University Fourth Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT02117024 Comparator | Jul 2014 → Dec 2017 | non-small cell lung carcinoma | Heat Biologics | Terminated | No outcome recorded |
| Phase 2 | NCT02299999 Comparator | Apr 2014 → Dec 2022 overdue | breast cancer | UNICANCER | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02791373 Comparator | Mar 2014 → Dec 2017 | amyloidosis, plasma cell myeloma | Insel Gruppe AG, University Hospital Bern | Completed | No outcome recorded |
| Phase 2 | NCT01843647 Comparator | Apr 2013 → Dec 2016 | non-small cell lung carcinoma | Betta Pharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT01835236 Comparator | Mar 2013 → Jan 2018 | breast cancer | Swiss Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT01850147 Background | Mar 2013 → Oct 2014 | lung cancer | Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT01703910 Comparator | Nov 2012 | colon adenocarcinoma, metastatic neoplasm, rectum adenocarcinoma | Spanish National Cancer Research Centre | Completed | No outcome recorded |
| Phase 2 | NCT01683175 Comparator | Aug 2012 → Oct 2020 | non-small cell lung carcinoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT01137994 Background | Oct 2011 → Dec 2016 | breast neoplasm | GlaxoSmithKline | Withdrawn | No outcome recorded |
| Phase 2 | NCT01533727 Background | Aug 2011 → Dec 2017 | non-small cell lung carcinoma | Sun Yat-sen University | Withdrawn | No outcome recorded |
| Phase 2 | NCT01410214 Comparator | May 2011 → Jul 2015 | non-small cell lung carcinoma | Chinese Lung Cancer Surgical Group | Unknown | No outcome recorded |
| Phase 2 | NCT01222715 Background | Oct 2010 → Jun 2015 | alveolar rhabdomyosarcoma, childhood pleomorphic rhabdomyosarcoma, rhabdomyosarcoma with mixed embryonal and alveolar features | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT01038037 Background | Jan 2010 → Jun 2013 | non-small cell lung carcinoma | Vejle Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT01097317 Background | Sep 2009 → Sep 2011 | chemotherapy-induced toxicity, lung carcinoma, musculoskeletal system disorder | Wales Cancer Trials Unit | Unknown | No outcome recorded |
| Phase 2 | NCT00887783 Background | May 2009 → Sep 2016 | non-small cell lung carcinoma | Odense University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01128543 Comparator | Apr 2009 → Mar 2012 | cancer | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00842712 Background | Feb 2009 → Jul 2013 | non-small cell lung carcinoma | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 2 | NCT01687439 Background | Dec 2008 → Oct 2009 | non-small cell lung carcinoma | Fudan University | Completed | No outcome recorded |
| Phase 2 | NCT00643565 Background | Jul 2008 → May 2015 | sarcoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT00503750 Comparator | Apr 2008 → Jul 2011 | breast cancer | Emory University | Completed | No outcome recorded |
| Phase 2 | NCT00636311 Background | Feb → Apr 2008 | Hodgkins lymphoma | Istituto Clinico Humanitas | Completed | No outcome recorded |
| Phase 2 | NCT00597116 Comparator | Dec 2007 → Jan 2010 | malignant mesothelioma | Genzyme, a Sanofi Company | Terminated | No outcome recorded |
| Phase 2 | NCT00476827 Comparator | May 2007 → May 2011 | breast cancer | Duke University | Terminated | No outcome recorded |
| Phase 2 | NCT00381940 Background | Jan 2007 → Jun 2008 | Hodgkin's lymphoma, lymphocytic depletion, Hodgkin's lymphoma, mixed cellularity, adult nodular lymphocyte predominant Hodgkin lymphoma, nodular sclerosis classical Hodgkin lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00349089 Comparator | Sep 2006 → Apr 2014 | non-small cell lung carcinoma | Thoraxklinik-Heidelberg gGmbH | Completed | No outcome recorded |
| Phase 2 | NCT00678964 Comparator | Jun 2006 → Nov 2008 | non-small cell lung carcinoma | LungenClinic Grosshansdorf | Unknown | No outcome recorded |
| Phase 2 | NCT00325234 Comparator | Jun 2006 → Apr 2010 | breast cancer | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00337194 Background | Apr 2006 → Sep 2008 | Hodgkin's lymphoma, lymphocytic depletion, Hodgkin's lymphoma, mixed cellularity, adult nodular lymphocyte predominant Hodgkin lymphoma, nodular sclerosis classical Hodgkin lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00246571 Comparator | Jan 2006 → May 2010 | breast neoplasm | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00278070 Comparator | Jan 2006 → Feb 2008 | breast cancer, non-small cell lung carcinoma, prostate cancer | Hellenic Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00130507 Background | Nov 2005 → Jun 2009 | breast cancer | Spanish Breast Cancer Research Group | Terminated | No outcome recorded |
| Phase 2 | NCT00083083 Background | Mar 2005 → Jun 2006 | lung cancer | American College of Radiology Imaging Network | Unknown | No outcome recorded |
| Phase 2 | NCT00532623 Comparator | May 2004 → Sep 2006 | breast cancer | National Cancer Center, Korea | Completed | No outcome recorded |
| Phase 2 | NCT00148668 Comparator | Dec 2003 → Jan 2009 | breast cancer | Eric Winer, MD | Completed | No outcome recorded |
| Phase 2 | NCT00163761 Comparator | Dec 2002 → Feb 2008 | Hodgkins lymphoma, non-Hodgkin lymphoma | Bayside Health | Completed | No outcome recorded |
| Phase 2 | NCT00388349 Background | Sep 2001 → Mar 2008 | Hodgkins lymphoma | Stanford University | Completed | No outcome recorded |
| Phase 2/34 trials | ||||||
| Phase 2/3 | NCT02777788 Comparator | Sep 2014 → Dec 2019 | cancer | Shanghai University of Traditional Chinese Medicine | Unknown | No outcome recorded |
| Phase 2/3 | NCT02213744 Comparator | Jul 2014 → Dec 2016 | HER2 positive breast carcinoma | Merrimack Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2/3 | NCT00312819 Background | Mar 2006 → Dec 2009 | non-small cell lung carcinoma | Hadassah Medical Organization | Completed | No outcome recorded |
| Phase 2/3 | NCT00169104 Comparator | Jul 2002 → Mar 2009 | breast cancer | Dartmouth-Hitchcock Medical Center | Terminated | No outcome recorded |
| Phase 379 trials | ||||||
| Phase 3 | NCT07556848 Comparator | May 2026 → Dec 2027 expected | triple-negative breast carcinoma | Mabwell (Shanghai) Bioscience Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07406542 Comparator | Apr 2026 → Apr 2029 expected | Her2-receptor negative breast cancer | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07533123 Comparator | Mar 2026 → Mar 2029 expected | triple-negative breast carcinoma | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Recruiting | No outcome recorded |
| Phase 3 | NCT07461454 Comparator | Mar 2026 → Dec 2027 expected | breast cancer | MediLink Therapeutics (Suzhou) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06908993 Comparator | Dec 2025 → Mar 2028 expected | non-small cell lung carcinoma | French Cooperative Thoracic Intergroup | Recruiting | No outcome recorded |
| Phase 3 | NCT06908304 Comparator | Dec 2025 → Jul 2027 expected | non-small cell lung carcinoma | Maia Biotechnology | Recruiting | No outcome recorded |
| Phase 3 | NCT07047365 Background | Jul 2025 → Jun 2028 expected | HER2 positive breast carcinoma | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06564844 Comparator | Oct 2024 → Jun 2027 expected | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06435429 Background | Aug 2024 → Apr 2028 expected | HER2 positive breast carcinoma | Jazz Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT06519370 Comparator | Aug 2024 → Aug 2026 overdue | triple-negative breast carcinoma | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06459180 Comparator | Jul 2024 → Jun 2028 expected | cervical cancer | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06383767 Comparator | Jul 2024 → Jun 2027 expected | breast cancer | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07371910 Comparator | Jun 2024 → Mar 2031 expected | Her2-receptor negative breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06255392 Comparator | Jun 2024 → Mar 2031 expected | Her2-receptor negative breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT06268652 Comparator | Jan 2024 → Feb 2026 overdue | breast carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT06079983 Comparator | Dec 2023 → Apr 2026 overdue | breast cancer | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Recruiting | No outcome recorded |
| Phase 3 | NCT06081959 Comparator | Oct 2023 → Dec 2026 expected | breast cancer | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06143553 Comparator | Sep 2023 → Dec 2025 overdue | breast cancer | Shanghai Yizhong Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT05901935 Comparator | Jul 2023 → Jan 2026 overdue | HER2 positive breast carcinoma | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05806060 Comparator | Apr 2023 → May 2026 overdue | triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT05487391 Background | Dec 2022 → Aug 2027 expected | non-small cell lung carcinoma | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT05244642 Comparator | Feb 2022 → Dec 2025 | Hodgkins lymphoma | Akeso | Unknown | No outcome recorded |
| Phase 3 | NCT05134194 Background | Jan 2022 | triple-negative breast carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Terminated | No outcome recorded |
| Phase 3 | NCT05104866 Comparator | Oct 2021 → Jul 2024 overdue | breast cancer | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05346861 Background | Sep 2021 → Oct 2023 | HER2 positive breast carcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 3 | NCT05063786 Comparator | Sep 2021 → Jun 2026 overdue | breast cancer | Spanish Breast Cancer Research Group | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04943627 Comparator | Aug → Oct 2021 | cancer of unknown primary site, cervical cancer | Agenus Inc. | Withdrawn | No outcome recorded |
| Phase 3 | NCT04697628 Comparator | Feb 2021 → Jul 2023 | cervical cancer | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT04639986 Comparator | Nov 2020 → Dec 2026 expected | breast cancer | Gilead Sciences | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04400695 Comparator | Sep 2020 → Jun 2024 | breast cancer | RemeGen Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT04342936 Comparator | Jul 2020 → Aug 2023 | classic Hodgkin lymphoma | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT04296370 Comparator | Jul 2020 → Jun 2022 | Her2-receptor negative breast cancer | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT03901339 Comparator | May 2019 → Oct 2023 | breast cancer | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT03656393 Comparator | Aug 2018 → Jul 2020 | non-small cell lung carcinoma | Shenzhen People's Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT03456076 Comparator | Aug 2018 → Jun 2023 overdue | non-small cell lung carcinoma | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03529279 Comparator | Jun 2018 → Jun 2026 | nasopharyngeal carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 3 | NCT03381066 Comparator | Apr 2018 → Dec 2022 | — | Yonsei University | Unknown | No outcome recorded |
| Phase 3 | NCT03262935 Comparator | Dec 2017 → Mar 2021 | breast cancer | Byondis B.V. | Completed | No outcome recorded |
| Phase 3 | NCT02574455 Comparator | Nov 2017 → Mar 2020 | breast cancer | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02991482 Comparator | Sep 2017 → Feb 2019 | malignant pleural mesothelioma | ETOP IBCSG Partners Foundation | Completed | No outcome recorded |
| Phase 3 | NCT03191786 Comparator | Sep 2017 → Apr 2022 | non-small cell lung carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT03203590 Comparator | Sep 2017 → Jan 2026 | — | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 3 | NCT02998528 Comparator | Mar 2017 → Sep 2021 | non-small cell lung carcinoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT02974426 Background | Nov 2016 → Feb 2024 | non-small cell lung carcinoma | Shanghai Chest Hospital | Terminated | No outcome recorded |
| Phase 3 | NCT02915744 Comparator | Nov 2016 → Jul 2020 | breast cancer, metastatic neoplasm | Nektar Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT02579564 Background | Oct 2016 → Jun 2018 | non-small cell lung carcinoma | Xinqiao Hospital of Chongqing | Unknown | No outcome recorded |
| Phase 3 | NCT02795884 Comparator | Jun 2016 → Nov 2020 | non-small cell lung carcinoma | Yonsei University | Withdrawn | No outcome recorded |
| Phase 3 | NCT02644252 Background | Jan 2016 → May 2019 | lung cancer | Vejle Hospital | Terminated | No outcome recorded |
| Phase 3 | NCT02486718 Background | Oct 2015 → Jan 2024 overdue | non-small cell lung carcinoma | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02555657 Comparator | Oct 2015 → Apr 2019 | triple-negative breast carcinoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT02492711 Background | Aug 2015 → Aug 2021 | HER2 positive breast carcinoma, metastatic neoplasm | MacroGenics | Completed | No outcome recorded |
| Phase 3 | NCT02514681 Background | Aug 2015 → Dec 2018 | HER2 positive breast carcinoma | Japan Breast Cancer Research Group | Completed | No outcome recorded |
| Phase 3 | NCT02448797 Comparator | Jun 2015 → Jun 2022 | non-small cell lung carcinoma | Betta Pharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT02352948 Comparator | Jan 2015 → Feb 2018 | non-small cell lung carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT02000622 Comparator | Mar 2014 → Dec 2016 | BRCA1-related cancer predisposition, BRCA2-related cancer predisposition, breast carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT01945775 Comparator | Oct 2013 → Sep 2017 | BRCA1-related cancer predisposition, BRCA2-related cancer predisposition, breast cancer | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT02225470 Comparator | Sep 2013 → Sep 2017 | female breast carcinoma, triple-negative breast carcinoma | Eisai Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01950182 Comparator | Sep 2013 → May 2020 | breast cancer | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 3 | NCT01619111 Comparator | Feb 2012 → Jan 2022 | HER2 positive breast carcinoma, Her2-receptor negative breast cancer | University of Ulm | Completed | No outcome recorded |
| Phase 3 | NCT01454934 Comparator | Dec 2011 → May 2014 | non-small cell lung carcinoma | Eisai Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01492101 Comparator | Dec 2011 → Apr 2016 | female breast carcinoma | Nektar Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT03117335 Background | Nov 2011 → Nov 2016 | non-small cell lung carcinoma | Jiangsu Wuzhong Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT01405079 Comparator | Sep 2011 → Mar 2017 | non-small cell lung carcinoma | Guangdong Association of Clinical Trials | Unknown | No outcome recorded |
| Phase 3 | NCT01125566 Background | Jun 2010 → Jun 2013 | breast cancer | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT01098266 Background | Apr 2010 → Apr 2014 | malignant pleural mesothelioma | AGC Biologics S.p.A. | Completed | No outcome recorded |
| Phase 3 | NCT01007942 Background | Oct 2009 → Jun 2015 | HER2 positive breast carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00820755 Comparator | Jan 2009 → Dec 2011 | non-small cell lung carcinoma | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 3 | NCT00686959 Comparator | Sep 2008 → Oct 2014 | non-small cell lung carcinoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00737867 Comparator | Sep 2007 → Feb 2011 | non-small cell lung carcinoma | The Norwegian Lung Cancer Study Group | Completed | No outcome recorded |
| Phase 3 | NCT00659269 Background | Jul 2006 → Jun 2013 | cancer | New Mexico Cancer Research Alliance | Completed | No outcome recorded |
| Phase 3 | NCT00298415 Comparator | Mar 2006 → Sep 2010 | non-small cell lung carcinoma | French Cooperative Thoracic Intergroup | Completed | No outcome recorded |
| Phase 3 | NCT00281697 Background | Feb 2006 → Mar 2009 | breast cancer | Genentech, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00148798 Background | Oct 2004 → Jul 2007 | non-small cell lung carcinoma | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 3 | NCT00088530 Comparator | Jul 2004 → Feb 2010 | non-Hodgkin lymphoma | CTI BioPharma | Completed | No outcome recorded |
| Phase 3 | NCT00055887 Background | Nov 2002 → ? | lung cancer | Spectrum Pharmaceuticals, Inc | Withdrawn | No outcome recorded |
| Phase 3 | NCT00042315 Background | Jun 2002 → Jun 2003 | non-small cell lung carcinoma | QLT Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT00431106 Comparator | Apr 2002 → Jan 2009 | breast cancer | Hellenic Oncology Research Group | Completed | No outcome recorded |
| Phase 3 | NCT00017459 Background | Jul 2000 → Feb 2004 | lung cancer | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00002583 Comparator | Jul 1994 → Apr 2004 | lung cancer | NCIC Clinical Trials Group | Completed | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT06230055 Background | Jan 2024 → Jan 2026 overdue | Her2-receptor negative breast cancer, malignant leptomeningeal tumor | Fudan University | Recruiting | No outcome recorded |
| Phase 4 | NCT05583188 Background | Feb 2023 → Feb 2024 | non-small cell lung carcinoma | Galvanize Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 4 | NCT02497118 Background | Aug 2010 → Apr 2015 | non-small cell lung carcinoma | Tianjin Medical University Cancer Institute and Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01196078 Comparator | Feb 2007 → Dec 2010 | non-small cell lung carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT06857747 Background | Mar → Dec 2025 | breast cancer | QIAO LI | Unknown | No outcome recorded |
| — | NCT06081400 Comparator | Mar 2024 → Mar 2027 expected | desmoid tumor | University Hospital, Strasbourg, France | Recruiting | No outcome recorded |
| — | NCT01209520 Background | Jul 2009 → Dec 2013 | non-small cell lung carcinoma | University of Miami | Completed | No outcome recorded |
Evidence & citations 33 cited values
Every value below carries the sentence it was read from. 526 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vinorelbine | “including but not limited to DHAP (dexamethasone, cisplatin, high-dose cytarabine), ESHAP (etoposide, methylprednisolone, high-dose cytarabine and cisplatin), DICE...” NCT04486391 ↗486“Any of the following single-agent chemotherapy may be given at the discretion of the investigator, with a cycle length not to exceed four weeks: Capecitabine, Vinorelbine,...” NCT01156753 ↗ “Participants will receive 6 cycles of a standard intravenous or oral chemotherapy regimen or an Antibody-Drug Conjugate (ADC), selected by the investigator from...” NCT07371910 ↗ “Drugs may include all or a subset of the following which each may be tested as single agents or in any number of combinations including, but not limited to: Lenvatinib,...” NCT05553782 ↗ “Patients in the TPC arm of the study will be treated with one or a combination of the following: carboplatin, taxanes, capecitabine, gemcitabine, vinorelbine or eribulin in...” NCT06072612 ↗ “In the Tailored chemotherapy arm, 7 different combination chemotherapy regimens that containing 2 drugs among taxotere, epirubicin, cisplatin, vinorelbine, and 5FU, will be...” NCT00776724 ↗ “The study is aimed to evaluate the efficacy of investigator's choice (ICC) of chemotherapy (nab-paclitaxel, capecitabine, eribulin, carboplatin, vinorelbine, or utidelone)...” NCT05954442 ↗ “Induction treatment: 2 cyles of Q3W second-line plantium-based chemotherapy according to standard of care: Cisplatin or carboplatin in combination with pemetrexed, paclitaxel,...” NCT05383001 ↗ “Carboplatin, cisplatin, paclitaxel, docetaxel, gemcitabine, vinorelbine, pemetrexed, or erlotinib administered on Day 1 of every 21-day cycle except gemcitabine, which was...” NCT00312728 ↗ “patient will receive 2 cycles of cisplatine 80 mg/m² at day 29 and day 50 more vinorelbine 15 mg/m² at day 29, day 36 and day 50 and 57 associated to cetuximab 400 mg/m² at...” NCT00985855 ↗ “Participants will receive investigator's choice of chemotherapy determined prior to randomization from 1 of the 4 allowed regimens as per protocol: eribulin, or vinorelbine or...” NCT07556848 ↗ “Chidamide 20 mg orally;gemcitabine 1g/m2, twice a week, intravenous infusion on day 1, vinorelbine 20 mg/m2, infusion on day 1; Mitoxantrone Hydrochloride Liposome12 mg/m2,...” NCT06211881 ↗ “could be single-agent gemcitabine (1000-1250 mg/m2 intravenously), vinorelbine (25 mg/m2 intravenously or 60 mg/m2 orally), doxorubicin (60-75 mg/m2 intravenously), or best...” PMID 29753703 ↗ May 2018 “The other drug must contain one of the following: etoposide, vinorelbine, vinblastine, pemetrexed, taxanes (e.g., paclitaxel, docetaxel, albumin paclitaxel, paclitaxel...” NCT06424899 ↗ “Taxanes (paclitaxel, docetaxel, liposomal paclitaxel, nabpaclitaxel), vinorelbine, capecitabine, eribulin, and other chemotherapeutic agents indicated in advanced breast cancer...” NCT05621434 ↗ “One of the following Treatment of Physician Choice will be administered per standard of care: eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel” NCT01492101 ↗ “Drugs used in chemotherapy, such as cisplatin and vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.” NCT00309972 ↗ “METHODS: This phase II, multicenter, randomized, double-blinded study assessed the safety and efficacy of adding of disulfiram to cisplatin and vinorelbine for six cycles.” PMID 25777347 ↗ Mar 2015 “Chemotherapy: Capecitabine Tablets, Gemcitabine Hydrochloride for Injection, Vinorelbine Tartrate Injection and Eribulin Mesylate Injection are Chemotherapy Drugs” NCT07047365 ↗ “Gemox: Gemcitabine and Oxaliplatin； IGEV: Ifosfamide, Gemcitabine, Vinorelbine, and Prednisolone； DHAP: Dexamethasone, high-dose Cytarabine (Ara-C) and Cisplatin.” NCT04342936 ↗ “chemotherapy, single agent including docetaxel, albumin-bound paclitaxel, vinorelbine, gemcitabine, pemetrexed, or paclitaxel, as determined by the investigator” NCT01850147 ↗ “Chemotherapy selected by doctors: albumin bound paclitaxel, vinorelbine, gemcitabine, capecitabine, and aribrin were administered according to clinical routine;” NCT04681287 ↗ “A Phase 1 Study of Vinorelbine Liposomes Injection (VLI) for Treatment in Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Disease” NCT00364676 ↗ “A1: docetaxel 60mg/m2 on Day 1 vinorelbine 20mg/m2 on Day 1 and Day 8 (DV) A2: gemcitabine 1000mg/m2 on Day 1 vinorelbine 25mg/m2 on Day 1 and Day 8 (GV)” NCT01648517 ↗ “Drugs considered acceptable as SSCC: paclitaxel; nab-paclitaxel; eribulin; pegylated liposomal doxorubicin (PLD); vinorelbine; gemcitabine; capecitabine.” NCT01698281 ↗ “or vinorelbine : for adults: 90mg/week (per os: 3x30mg, soft capsules) for 12 months. for adolescents: 60mg/m2/week (capped at 90mg/week) for 12 months” NCT06081400 ↗ “Systematic chemotherapy: including capecitabine(1000mg/m2 bid, d1-14, q3w, po), gemcitabine(1000mg/m2, d1,8, q3w, ivgtt), vinorelbine(60mg/m2, qw, po)” NCT06230055 ↗ “After surgery patients receive 4-cycle adjuvant chemotherapy with vinorelbine /cisplatin regimen, until untolerable toxicity or disease progression.” NCT01843647 ↗ “Patients with pathologically proven untreated NSCLC, receiving 1st line cisplatin-vinorelbine and with an assessable lesion were eligible.” PMID 25674536 ↗ Jan 2015 “Ivonescimab (20mg/kg, Q3W) combined with chemotherapy (pemetrexed 500mg/m², gemcitabine 1000mg/m², or vinorelbine 25mg/m²) for 4 cycles.” NCT06875076 ↗ “Palliative chemotherapy regimen includes Eribulin, Gemcitabine, Utidelone and Vinorelbine, by the treatment of physician's choice (TPC).” NCT06678048 ↗ “The chemotherapy regimen will consist of standard second-line agents such as capecitabine, eribulin, vinorelbine, or gemcitabine.” NCT07657130 ↗ “intravenous chemotherapy (vinorelbine 25 mg/m2 on days 1 and 8 of each cycle plus cisplatin 75 mg/m2 on day 1 of each cycle” PMID 34280355 ↗ Jul 2021 “chemotherapy may be a)gemcitabine/cisplatin, b)vinorelbine + cisplatin/docetaxel + cisplatin or c)vinorelbine or docetaxel” NCT00642824 ↗ “The significant efficacy and good safety profile of Vinorelbine in the treatment of advanced breast cancer are accepted.” NCT03854617 ↗ “Pembrolizumab (200 mg) plus chemotherapy (physicians' choice among docetaxel, pemetrexed, or vinorelbine) every 3 weeks” NCT03656094 ↗ “The choice of chemotherapy plus immunotherapy for squamous cell carcinoma is gemcitabine or paclitaxel or vinorelbine.” NCT06032052 ↗ “Investigator's choice of monotherapy chemotherapy (Eribulin, Capecitabine, Gemcitabine, Vinorelbine, or Taxanes.)” NCT06775236 ↗ “Chemotherapy of Physician's Choice, including nab-paclitaxel, Eribulin, Capecitabine, Vinorelbine, Gemcitabine.” NCT07203729 ↗ “2. Vinorelbine - 25-30 mg/m2 rapid intravenous infusion or 60-80 mg/m2 oral weekly, expressed in 3-week cycles” NCT00246571 ↗ “Chemotherapy regimen is chosen from the following: Vinorelbine, Gemcitabine, taxanes or Eribulin monotherapy” NCT05346861 ↗ “Monochemotherapy (containing one of the following): docetaxel, paclitaxel, vinorelbine, capecitabine, NPLD” NCT01619111 ↗ “Vinorelbine 25 mg/m2 IV, weekly for 3 consecutive weeks followed by 1-week rest. Totally 80 cycles.” NCT04881838 ↗ “Treatment of Physicians' Choice (albumin-paclitaxel, capecitabine, vinorelbine, and irbribulin)” NCT05594095 ↗ “GVD regimen is a chemotherapy regimen consisted by Gemcitabine, Vinorelbine and Doxorubicine.” NCT03346642 ↗ “Patients receive vinorelbine IV on days 1 and 8, and docetaxel IV over 1 hour on day 1 only.” NCT00006682 ↗ “Drug: Vinorelbine Day 1 Vinorelbine 20mg/mq for a maximum of 4 cycles Other Name: Navelbine” NCT05660993 ↗ “Vinorelbine: 25mg/ m2 on days 1 and 8 of each cycle, 1 cycle in 21 days, IV drip” NCT06375707 ↗ “Vinorelbine:25 mg/m2, IV (in the vein) on day 1 and Day 8 of each 21 day cycle.” NCT05347134 ↗ “Second-line: Investigator's choice (pemetrexed, gemcitabine, or vinorelbine).” NCT07131345 ↗ “or intravenous vinorelbine 25-30 mg/m2 on days 1 and 8 of each 21-day cycle” PMID 41308673 ↗ Dec 2025 “Vinorelbine (Navelbine®): 25-30 mg/m2 on days 1 and 8 of a 21-day cycle” NCT02492711 ↗ “Vinorelbine (Navelbine) 30 mg/m\^2 IV every week of each 3-week cycle.” NCT00281697 ↗ “Vinorelbine soft capsules 40 mg, orally (PO), three times weekly (tiw)” NCT07589972 ↗ “Capecitabine , Vinorelbine, or Gemcitabine combined with trastuzumab” NCT01950182 ↗ “maintenance chemotherapy (low-dose cyclophosphamide and vinorelbine)” PMID 35709412 ↗ Jun 2022 “Vinorelbine: 20 mg orally, every other day, every 3 weeks (q3w).” NCT06839560 ↗ “CIV chemotherapy (cyclophosphamide +Irinotecan + vinorelbine)” NCT06816771 ↗ “Vinorelbine 30 mg/m2 IV Day 1 and Day 8, repeat every 21 days” NCT02000622 ↗ “Gemcitabine, vinorelbine, capecitabine, eribulin or a taxane” NCT02448420 ↗ “Vinorelbine, 25mg/m2, iv, on d1 and d8 in each 21-day cycle” NCT03117335 ↗ “or vinorelbine (25mg/m\^2 on day 1,8,15 of a 28 day cycle)” NCT01802970 ↗ “Drug: Chosen Chemotherapy (Vinorelbine) Vinorelbine -IV” NCT04398108 ↗ “Vinca alkaloids (Vinorelbine, Vinblastine, Vincristine)” NCT02299999 ↗ “Vinorelbine (20 mg/m2 IV over 10 min on days 1 and 8)” NCT00011414 ↗ “vinorelbine 25 mg/m\^2 on Day 1 (D1) and Day 8 (D8)” NCT00820755 ↗ “Capecitabine, Eribulin, Gemcitabine or Vinorelbine” NCT01945775 ↗ “Vinorelbine 20mg orally, once every other day, Q3W” NCT06771609 ↗ “Vinorelbine 25 mg/m² as a \< 10 min i.v. infusion” NCT00544765 ↗ “Vinorelbine (25mg/m\^2) on day 1,8, every 3 weeks” NCT05299164 ↗ “vinorelbine 25 mg/m2 d1,8 ivgtt , every 3 weeks” NCT05806060 ↗ “cisplatin and vinorelbine based chemotherapy” NCT01118676 ↗ “The combination of vinorelbine and cisplatin” NCT03529279 ↗ “Vinorelbine (qwk, 10, 15, 20 or 25 mg/m2),” NCT00002949 ↗ “vinorelbine (30mg, oral, tiw, D1/D3/D5)” NCT06416930 ↗ “Vinorelbine 25mg/m2，day 1 and day 8” NCT06176534 ↗ “Vinorelbine (20mg/m\^2) on day 1,8” NCT06244368 ↗ “vinorelbine 25-30mg/m2 d1, d8 q3w” NCT01533727 ↗ “Vinorelbine tartrate (Navelbine)” NCT00659269 ↗ “Vinorelbine Tartrate Injection” NCT04400695 ↗ “Vinorelbine 20 mg/m2 at day 1” NCT01333605 ↗ “Vinca alkaloid: Vinorelbine” NCT03257267 ↗ “vinorelbine 25 mg/m² d1,d8” NCT06145308 ↗ “vinorelbine + platinum” NCT00391586 ↗ “vinorelbine 20mg/m2 D1” NCT05244642 ↗ “Vinorelbine (Vino)” NCT03262935 ↗ “Drug: Vinorelbine” NCT05583110 ↗ “Vinorelbine” NCT05347134 ↗ “Vinorelbine” NCT01703910 ↗ “Vinorelbine” NCT01520103 ↗ “Vinorelbine” NCT05583188 ↗ |
| Known as | - Vinorelbine, Navelbine | “- Vinorelbine, Navelbine” NCT01220284 ↗1“Vinorelbine: Navelbine” NCT01802970 ↗ |
| Known as | intensive treatment | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05842525 ↗ |
| Known as | Liposomal vinorelbine tartrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL553025 ↗ |
| Known as | Navelbin | ChEMBL registry synonym — accepted as the source's own label CHEMBL553025 ↗ |
| Known as | Navelbine | “This clinical trail will combine the chemotherapy drugs, Estramustine and Vinorelbine (Navelbine), on an intermittent therapy strategy based on PSA response in the treatment of...” NCT00151086 ↗33“A Randomized Phase III Study of Trastuzumab (Herceptin) in Combination With Either Vinorelbine (Navelbine), or Taxane-based Chemotherapy in Patients With HER2 Overexpressing...” NCT00146549 ↗ “Vinorelbine (trade name Navelbine) is an anti-mitotic chemotherapy drug that is given as a treatment for some types of cancer, including breast cancer and non-small cell lung cancer.” NCT00014430 ↗ “Vinorelbine(Navelbine) is a third-line treatment option for Hodgkin's disease(HD) after transplantation failed, while both HD and ALCL express CD30.” NCT03397953 ↗ “Vinorelbine(Navelbine) is a third-line treatment option for Hodgkin's disease(HD) after transplantation failed, while both HD and ALCL express CD30.” NCT03443128 ↗ “Vinorelbine tartrate soft capsule (also named Navelbine; registration No. H20140657; Pierre Fabre Medicament, Boulogne, France) 40 mg once orally” NCT03932526 ↗ “They will receive one of the following drugs with tariquidar: doxorubicin (Adriamycin ), vinorelbine (Navelbine ), or docetaxel (Taxotere ).” NCT00011414 ↗ “Oxaliplatin is given intravenously every 21 days and Navelbine is administered Intravenously on day 1 and day 8 every 21 days.” NCT00238849 ↗ “A Phase I Absolute Bioavailability Study of Oral NAVELBINE (Vinorelbine Tartrate) in Patients With Solid Tumors” NCT00006088 ↗ “adjuvant chemotherapy with Xeloda (capecitabine), Methotrexate and Navelbine (vinorelbine tartrate) (XMN).” NCT00194779 ↗ “administration of a propranolol (HEMANGIOL®) and oral metronomic vinorelbine (NAVELBINE®) combination” NCT02897986 ↗ “Vinorelbine (Navelbine®): 25-30 mg/m2 on days 1 and 8 of a 21-day cycle” NCT02492711 ↗ “Vinorelbine (Navelbine) 30 mg/m\^2 IV every week of each 3-week cycle.” NCT00281697 ↗ “Vinorelbine 20mg/mq for a maximum of 4 cycles Other Name: Navelbine” NCT05660993 ↗ “Navelbine 25 mg/M2 in 250 cc NS over 60 min on day 1 and day 8” NCT00830544 ↗ “* Group A: Trastuzumab (Herceptin) + Vinorelbine (Navelbine)” NCT03414658 ↗ “The drug Navelbine is part of this class of drugs.” NCT00256815 ↗ “Oral Vinorelbine (Navelbine®)20mg x 2/week” NCT00908869 ↗ “Vinorelbine Tartrate (Navelbine)” NCT00675597 ↗ “Navelbine IVD 25 mg/m2 D1、D8” NCT03359694 ↗ “vinorelbine (Navelbine®)” NCT00103233 ↗ “Vinorelbine (Navelbine)” NCT00165334 ↗ |
| Known as | Navelbine oral | “Oral Vinorelbine (Navelbine oral) 50 mg 3 times weekly, monday, wednesday and friday plus Capecitabine (Xeloda) 1000 mg/m2 2 times daily day 1-14 in a 3 weekly schedule.” NCT01941771 ↗ |
| Known as | NSC-608210 | “Docetaxel (NSC-628503) And Vinorelbine (NSC-608210) Plus Filgrastim (NSC-614629) With Weekly Trastuzumab (NSC-688097) For HER-2 Positive, Stage IV Breast Cancer” NCT00041067 ↗ |
| Known as | NSC-760087 | ChEMBL registry synonym — accepted as the source's own label CHEMBL553025 ↗ |
| Known as | NVB | “NVB” NCT02489409 ↗ |
| Known as | Oral Vinorelbine Tartrate | “Drug: Oral Vinorelbine Tartrate” NCT05823623 ↗ |
| Known as | TLC178 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02925000 ↗ |
| Known as | Vin | “Vinorelbine (Vin) will be administered at a dose of 25 mg/m\^2 as intravenous infusion on Days 1 and 8.” NCT00842712 ↗1“gemcitabine (Gem) with vinorelbine (Vin), etoposide (Eto), cisplatin (Cis), or carboplatin (Car).” PMID 22031232 ↗ Jan 2012 |
| Known as | Vinorelbin | “Vinorelbin: i.v. 25 mg/ m² d1, d8, d15 3qw until progress” NCT01520103 ↗ |
| Known as | Vinorelbina | ChEMBL registry synonym — accepted as the source's own label CHEMBL553025 ↗ |
| Known as | Vinorelbine (as tartrate) | ChEMBL registry synonym — accepted as the source's own label CHEMBL553025 ↗ |
| Known as | Vinorelbine (Navelbine oral) | “Vinorelbine (Navelbine oral)” NCT01941771 ↗ |
| Known as | Vinorelbine (Vino) | “Vinorelbine (Vino)” NCT03262935 ↗ |
| Known as | Vinorelbine base | ChEMBL registry synonym — accepted as the source's own label CHEMBL553025 ↗ |
| Known as | Vinorelbine ditartarate | ChEMBL registry synonym — accepted as the source's own label CHEMBL553025 ↗ |
| Known as | vinorelbine ditartrate | “Patients receive oral vinorelbine ditartrate once daily on days 1 and 8 and oral prednisone once daily on days 1-21.” NCT00627354 ↗ |
| Known as | Vinorelbine liposomal | ChEMBL registry synonym — accepted as the source's own label CHEMBL553025 ↗ |
| Known as | vinorelbine tartrate | “An Open-Label Phase II Study of Navelbine (Vinorelbine Tartrate) and Taxotere (Docetaxel) as First-Line Therapy for Metastatic Breast Cancer” NCT00006682 ↗34“Patients receive vinorelbine tartrate IV over 6-10 minutes and gemcitabine hydrochloride IV over 100 minutes on days 1 and 8.” NCT00070304 ↗ “Patients receive ifosfamide IV over 24 hours on days 1-4 and vinorelbine tartrate IV over 6-10 minutes on days 1 and 5.” NCT00006760 ↗ “A Phase I Absolute Bioavailability Study of Oral NAVELBINE (Vinorelbine Tartrate) in Patients With Solid Tumors” NCT00006088 ↗ “Vinorelbine tartrate injection, 25 \~ 30 mg/m2 each time, intravenous drip” NCT05420779 ↗ “vinorelbine tartrate IV over 6-10 minutes on days 1, 8, and 15” NCT00194779 ↗ “vinorelbine (vinorelbine tartrate)” NCT00337194 ↗ “Vinorelbine Tartrate (Navelbine)” NCT00675597 ↗ “Vinorelbine tartrate injection” NCT06079983 ↗ “Vinorelbine Tartrate Injection” NCT07533123 ↗ “Drug: vinorelbine tartrate” NCT00093808 ↗ “Drug: Vinorelbine Tartrate” NCT03482362 ↗ “Drug: vinorelbine tartrate” NCT00863512 ↗ “Drug: Vinorelbine Tartrate” NCT05901935 ↗ “Drug: vinorelbine tartrate” NCT00641160 ↗ “Drug: vinorelbine tartrate” NCT00287963 ↗ “Drug: vinorelbine tartrate” NCT00026494 ↗ “Drug: vinorelbine tartrate” NCT00022152 ↗ “Drug: vinorelbine tartrate” NCT00003622 ↗ “Drug: vinorelbine tartrate” NCT00005838 ↗ “Drug: vinorelbine tartrate” NCT00008333 ↗ “Vinorelbine Tartrate Oral” NCT05603013 ↗ |
| Known as | Vinorelbine tartrate (1:2) | ChEMBL registry synonym — accepted as the source's own label CHEMBL553025 ↗ |
| Known as | Vinorelbine tartrate (Navelbine) | “Vinorelbine tartrate (Navelbine)” NCT00659269 ↗ |
| Known as | Vinorelbine: Navelbine,vinorelbine bitartrate injection | “Vinorelbine: Navelbine,vinorelbine bitartrate injection” NCT02223611 ↗ |
| Known as | Vinorelbine: Sandoz vinorelbine | “Vinorelbine: Sandoz vinorelbine” NCT01648517 ↗ |
| Known as | VNB | “oral metronomic vinorelbine (VNB) and letrozole versus either treatment alone in postmenopausal women with newly diagnosed untreated HR+ and HER2-negative, stage I-III operable...” NCT02802748 ↗ |
| Known as | VNR | “oral vinorelbine (VNR)” PMID 37402471 ↗ Jul 2023 |
| Known as | VRL | “metronomic oral vinorelbine (VRL; 30 mg/day)” PMID 33743073 ↗ Mar 2021 |
| Action | Inhibit | “vinorelbine, work in different ways to stop the growth of tumor cells” NCT00103233 ↗ |
| Modality | Small molecule | “vinorelbine, a semi-synthetic vinca alkaloid” PMID 19533657 ↗ Oct 2009 |
| Route | Intravenous | “vinorelbine IV over 6-10 minutes” NCT00002813 ↗ |